| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Debomoy K Lahiri | |
| Nigel H Greig | |||
| Arnold Brossi | |||
| Kumar Sambamurti | |||
| Gosse B Bruinsma | |||
| Qian-sheng Yu | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| tartrate | Q425046 | ||
| P304 | page(s) | 281-290 | |
| P577 | publication date | 2005-07-01 | |
| P1433 | published in | Current Alzheimer Research | Q5195031 |
| P1476 | title | An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease | |
| P478 | volume | 2 |
| Q92612287 | (-)-Phenserine Ameliorates Contusion Volume, Neuroinflammation, and Behavioral Impairments Induced by Traumatic Brain Injury in Mice |
| Q28539914 | (-)-Phenserine attenuates soman-induced neuropathology |
| Q47723432 | (-)-Phenserine inhibits neuronal apoptosis following ischemia/reperfusion injury. |
| Q42803197 | A computer-automated touchscreen paired-associates learning (PAL) task for mice: impairments following administration of scopolamine or dicyclomine and improvements following donepezil |
| Q35893873 | Acetylcholinesterase inhibition ameliorates deficits in motivational drive |
| Q54288058 | Aerobic Radical-Cascade Alkylation/Cyclization of α,β-Unsaturated Amides: an Efficient Approach to Quaternary Oxindoles. |
| Q28488088 | Age-dependent neuroplasticity mechanisms in Alzheimer Tg2576 mice following modulation of brain amyloid-β levels |
| Q34387126 | Age-related decline in associative learning in healthy Chinese adults |
| Q36942970 | Alzheimer's disease drug development in 2008 and beyond: problems and opportunities |
| Q37163279 | Cholinesterase inhibitors improve both memory and complex learning in aged beagle dogs. |
| Q38865916 | Cognitive Translation Using the Rodent Touchscreen Testing Approach |
| Q38051975 | Consideration of species differences in developing novel molecules as cognition enhancers |
| Q42223095 | Crystal structure of phenyl N-(3,5-di-methyl-phenyl)carbamate |
| Q35900243 | Crystal structures of 4-chloro-phenyl N-(3,5-di-nitro-phen-yl)carbamate and phenyl N-(3,5-di-nitro-phen-yl)carbamate |
| Q40107907 | Differential effects of two hexahydropyrroloindole carbamate-based anticholinesterase drugs on the amyloid beta protein pathway involved in Alzheimer's disease |
| Q64105351 | Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease |
| Q47677964 | Does traumatic brain injury hold the key to the Alzheimer's disease puzzle? |
| Q37851509 | Drug delivery strategies for Alzheimer's disease treatment. |
| Q99557504 | Drug repositioning and repurposing for Alzheimer disease |
| Q37524877 | Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances? |
| Q37122955 | Immobilized butyrylcholinesterase in the characterization of new inhibitors that could ease Alzheimer's disease |
| Q50333044 | Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses |
| Q37029685 | Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine |
| Q35579234 | Investigational drugs for the treatment of AD: what can we learn from negative trials? |
| Q27677846 | Kinetics of Torpedo californica acetylcholinesterase inhibition by bisnorcymserine and crystal structure of the complex with its leaving group |
| Q34710672 | Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine |
| Q34338594 | Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine |
| Q36727886 | Molecular interaction study of N1-p-fluorobenzyl-cymserine with TNF-α , p38 kinase and JNK kinase. |
| Q37559812 | Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease |
| Q38914358 | Multifunctional activity of polyphenolic compounds associated with a potential for Alzheimer's disease therapy from Ecklonia cava |
| Q34575780 | Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease |
| Q38099889 | New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors |
| Q36349629 | Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer's disease |
| Q50678690 | Pharmacophore-based design and discovery of (-)-meptazinol carbamates as dual modulators of cholinesterase and amyloidogenesis. |
| Q36861622 | Phenserine |
| Q37510264 | Phenserine Efficacy in Alzheimer's Disease |
| Q36152393 | Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans |
| Q89717496 | Post-treatment with Posiphen Reduces Endoplasmic Reticulum Stress and Neurodegeneration in Stroke Brain |
| Q39789745 | Progress in the development of new drugs in Alzheimer's disease |
| Q38806779 | Recent progress in repositioning Alzheimer's disease drugs based on a multitarget strategy. |
| Q41467872 | Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine |
| Q37387281 | Resurrecting clinical pharmacology as a context for Alzheimer disease drug development |
| Q35592894 | Roles of p75(NTR), long-term depression, and cholinergic transmission in anxiety and acute stress coping |
| Q53347422 | Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: exploring the cholinergic anti-inflammatory pathway. |
| Q34940747 | Small molecule blockers of the Alzheimer Abeta calcium channel potently protect neurons from Abeta cytotoxicity |
| Q36455289 | Structure-property relationships of a class of carbamate-based fatty acid amide hydrolase (FAAH) inhibitors: chemical and biological stability |
| Q28818062 | Synthesis of the Alzheimer drug Posiphen into its primary metabolic products (+)-N1-norPosiphen, (+)-N8-norPosiphen and (+)-N1, N8-bisnorPosiphen, their inhibition of amyloid precursor protein, α-Synuclein synthesis, interleukin-1β release, and [...] |
| Q33829008 | Targeting Abeta and tau in Alzheimer's disease, an early interim report |
| Q34743671 | Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis |
| Q38958995 | The Paired Associates Learning (PAL) Test: 30 Years of CANTAB Translational Neuroscience from Laboratory to Bedside in Dementia Research |
| Q33790013 | The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen |
| Q36012226 | The anticholinesterase phenserine and its enantiomer posiphen as 5'untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression |
| Q55418661 | Translational inhibition of APP by Posiphen: Efficacy, pharmacodynamics, and pharmacokinetics in the APP/PS1 mouse. |
Search more.